Sage Therapeutics

Sage is developing novel drug candidates with the potential to transform the lives of people with brain health disorders. They focus our research and development efforts on modulation of GABA and NMDA receptors—two critical neurotransmitter systems. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS); NMDA is the major excitatory pathway. Both contribute significantly to regulating CNS function. Dysfunction in these two systems is known to be at the core of numerous depressive, neurological and neuropsychiatric disorders.